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Chemical regulators of epithelial 
plasticity reveal a nuclear receptor 
pathway controlling myofibroblast 
differentiation
Jon M. Carthy1,†, Martin Stöter2, Claudia Bellomo1,3, Michael Vanlandewijck1,‡, 
Angelos Heldin1, Anita Morén1, Dimitris Kardassis4, Timothy C. Gahman5, Andrew K. Shiau5, 
Marc Bickle2, Marino Zerial2, Carl-Henrik Heldin1 & Aristidis Moustakas1,3
Plasticity in epithelial tissues relates to processes of embryonic development, tissue fibrosis and cancer 
progression. Pharmacological modulation of epithelial transitions during disease progression may 
thus be clinically useful. Using human keratinocytes and a robotic high-content imaging platform, 
we screened for chemical compounds that reverse transforming growth factor β (TGF-β)-induced 
epithelial-mesenchymal transition. In addition to TGF-β receptor kinase inhibitors, we identified small 
molecule epithelial plasticity modulators including a naturally occurring hydroxysterol agonist of the 
liver X receptors (LXRs), members of the nuclear receptor transcription factor family. Endogenous 
and synthetic LXR agonists tested in diverse cell models blocked α-smooth muscle actin expression, 
myofibroblast differentiation and function. Agonist-dependent LXR activity or LXR overexpression 
in the absence of ligand counteracted TGF-β-mediated myofibroblast terminal differentiation and 
collagen contraction. The protective effect of LXR agonists against TGF-β-induced pro-fibrotic activity 
raises the possibility that anti-lipidogenic therapy may be relevant in fibrotic disorders and advanced 
cancer.
Epithelia compose a large part of human organs including the starting embryonic cell type. During embryogen-
esis, tissue homeostasis and disease pathogenesis, epithelia are remodelled locally by generating mesenchymal 
derivatives that migrate and establish new tissues in the embryonic cavities or assist in tissue wound healing after 
birth1. Prolonged tissue wounding with chronic inflammation causes mesenchymal constituents to contribute to 
tissue fibrosis and cancer progression instead of permitting physiological healing1. Under such developmental 
and pathological circumstances the process of epithelial-mesenchymal transition (EMT), a transient and revers-
ible change in epithelial differentiation that generates transitory mesenchymal cell types, becomes important1. 
EMT is induced by developmental growth factor pathways, among which transforming growth factor β (TGF-β ) 
has a prominent role2. EMT generates a spectrum of transitory cell phenotypes defined based on molecular mark-
ers that include transcription factors, cell-cell junctional proteins, cytoskeletal and extracellular matrix proteins 
and secreted cytokines3,4.
TGF-β not only induces EMT but also negatively regulates epithelial proliferation, induces epithelial cell death, 
and regulates many non-epithelial cell types in embryos and in adult tissues5. The signalling pathway of TGF-β 
is frequently misregulated in human diseases, including cancer and tissue fibrosis, a hallmark manifestation of 
TGF-β hyperactivity6. By binding to its type II and type I serine/threonine kinase receptors, TGF-β activates a 
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signalling cascade that involves Smad proteins and various branches of protein kinases, including mitogen acti-
vated protein kinases (MAPKs) and small GTPases, which coordinately affect gene expression to manifest the bio-
logical effects of this growth factor5. To catalyse EMT, TGF-β causes disassembly of cell-cell junctional complexes, 
remodels microfilaments and intermediate filaments, induces large amounts of extracellular matrix biomolecules, 
including fibronectin, and causes secretion of other cytokines and chemokines2. Furthermore, prolonged TGF-β 
activity in a given epithelial tissue is usually associated with the accumulation of newly deposited matrix, termi-
nal differentiation of myofibroblasts and recruitment of immune cells that contribute to the fibrotic phenotype7. 
Myofibroblasts, key cell types of the fibrotic microenvironment, can be derived from many sources including 
interstitial fibroblast progenitors, epithelial cells via EMT or endothelial cells via endothelial-mesenchymal tran-
sition7,8. Myofibroblasts generate tissue contractility which is catalysed by specialised α smooth muscle actin 
(α SMA) microfilaments and tight associations between the cytoskeleton, integrin family receptors and matrix 
proteins8. TGF-β activates transcriptional regulators, such as β -catenin and Smads, and MAPK signalling to con-
trol the activity of key transcription factors during myofibroblast differentiation, thus inducing the expression of 
αSMA and other fibrotic marker genes such as collagens and fibronectin8,9. Myofibroblast differentiation is also 
highly relevant to cancer; the tumour stroma contains cancer-associated fibroblasts (CAFs)10 that contribute to 
tumour cell invasiveness and immune surveillance suppression, mainly by secreting cytokines and chemokines, 
including TGF-β 11.
Our aim was to identify small molecules and molecular pathways that control terminal EMT stages linked to 
myofibroblast differentiation by using prolonged exposure of epithelial cells to TGF-β , followed by treatment with 
compounds from a chemical library. The rationale being that such an approach might identify selective inhibitors 
of the pro-tumourigenic actions of TGF-β which, in contrast to known TGF-β receptor kinase inhibitors, would 
not inhibit the tumour suppressor pathways of TGF-β . Agonists of the nuclear receptors, liver X receptor (LXR) 
α and β , were among the epithelial plasticity modulators identified in our screen. Being major regulators of 
lipid metabolism, the LXRs have been targeted pharmacologically12,13. By studying further the crosstalk between 
TGF-β and LXR in the context of myofibroblast differentiation, we have uncovered a novel mechanism via which 
LXRα can counteract the pro-fibrotic action of TGF-β .
Results
Selection of biological parameters to analyse EMT modulators. We screened several human cell 
models from diverse epithelial tissues (skin, lung, mammary) that exhibit TGF-β -mediated EMT in a time- and 
dose-dependent manner14. These included human immortalised keratinocytes HaCaT, human lung epithelial 
cells HPL1, human immortalised mammary epithelial cells HMLE, MCF-10A, a human mammary lumenal and 
a human mammary myoepithelial cell model. From these cell models, HaCaT keratinocytes, which were pre-
viously established to undergo EMT in response to TGF-β 15,16, appeared most suitable for the high-throughput 
assay (Fig. 1A). Several EMT markers, including the tight junction protein coxsackie and adenovirus receptor 
(CAR), the adherens junction protein E-cadherin, the extracellular matrix protein fibronectin, the intermediate 
filament protein vimentin (Fig. 1A) and a few more (adaptor protein ZO-1, tight junction membrane proteins 
occludin and claudins, actin microfilaments), were analysed in these cells before and after stimulation by TGF-β. 
For several makers signal-to-noise ratios and Z′ -factors17 were calculated. For the image analysis software the 
junctional protein markers, such as E-cadherin or ZO-1, were in general more difficult to quantify. Vimentin and 
actin staining revealed low signal-to-noise ratios. Taken together, we concluded that fibronectin (Fig. 1A, dashed 
box, Figs S1A and S2A) was the most reliable protein marker for a robotic microscope-based screen. Quantitative 
Z′-factor data convincingly showed that, for example, E-cadherin could not serve the same purpose (Fig. S2B). 
The choice of fibronectin is in agreement with a recently reported high-content screen preformed in a mammary 
epithelial cell model, which identified a set of kinase inhibitors affecting the EMT18.
HaCaT cells exhibit EMT as early as 36 h and more prominently at 48 or 72 h after addition of TGF-β (Fig. S1). 
Chemical inhibition of EMT was optimised using GW66004, a low molecular weight inhibitor of the TGF-β type 
I receptor kinase19. Incubation with GW6604 neutralised the autogenously secreted TGF-β and rendered HaCaT 
cultures more polarised with enhanced cell-cell adhesions. Adding GW6604 at different time points reversed 
TGF-β -induced EMT in HaCaT cells (Fig. S1). We adopted cell stimulations with TGF-β 1 for 72 h and inhibitor 
addition during the last 48 h.
High-content imaging optimisation using the TGF-β receptor kinase inhibitor. The assay was 
optimised for 96/384-well plate formats prior to the screen. In brief, several experimental conditions that also 
monitored sources of experimental variability, such as cell number, seeding conditions, antibody concentra-
tions and image analysis methods were tested and analysed as a multi-factorial matrix of combinations (man-
uscript in preparation). Using the ‘ArrayScan’ HCS platform, HaCaT images were automatically acquired and 
analysed to discriminate between the epithelial (fibronectin-negative; Fig. 1B) and mesenchymal phenotype 
(fibronectin-positive; Fig. 1B). In addition, the six repeated experiments were analysed using two different objec-
tive magnifications and two image analysis algorithms and routines. From the entire multi-factorial data set we 
extracted Z′ -factors calculated from cell populations exhibiting epithelial and mesenchymal phenotype. These 
values expressed the power by which the tested conditions for all measurements could discriminate between 
the two phenotypes. Finally, the most robust experimental conditions and measurements were chosen for a 
high-throughput screen. Two separate image analysis routines were developed to segment single cells or groups 
of cells as colonies. Among several hundred parameters measured, those measuring texture and relative intensity 
of fibronectin staining were the most reliable. A second set of parameters, nuclear density scattering and colony 
size-morphology were also very reliable for discriminating between epithelial (compact islets) and mesenchy-
mal (dispersed) phenotypes (Fig. 1C). Finally, using Z′ -factors and Pearson correlation coefficients from several 
hundred measurements, 18 parameters were selected to generate a multi-parametric profile. Among them were 
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Figure 1. Overview of the high-content screen. (A) Immunofluorescence microscopy with the indicated 
antibodies after 72 h stimulation of HaCaT cells with 5 ng/ml TGF-β . A dotted frame marks fibronectin 
expression. (B) HaCaT cell images taken with ArrayScan. Nuclear distribution (blue) and fibronectin expression 
(green) changes upon TGF-β stimulation. (C) HaCaT cell image analysis using BioApplications. Displayed are 
changes in nuclear distribution (first row); nuclear spreading (second row) with two algorithms segmenting 
single nuclei (red spots) and groups of cells as colonies (green lines); fibronectin expression (third row) and 
fibronectin analysed as intensity and texture measurements within single cells and colonies (fourth row, green 
lines). White bars indicate 10 μ m. (D) Schematic overview of data acquisition and analysis. 18 parameters 
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parameters for fibronectin, colony morphology, nuclear shape and distribution (Fig. S3A). Induction of EMT 
in HaCaT by TGF-β for 72 h was nearly completely reverted by co-treatment with 3.3 μ M GW6604 during the 
last 48 h (Fig. S2A), whereas co-treatment for 24 h or 36 h only partially inhibited EMT. As a proof-of-principle, 
we screened a small set of 78 compounds (mostly protein kinase inhibitors) first manually in a 96-well for-
mat at 7 concentrations (41 nM–30 μ M), and second, fully automated in a 384-well format at 8 concentrations 
(4.6 nM–10 μ M) using robotic liquid handling. The proof-of-principle screens in both plate formats showed that 
manual and robotic screening gave similar results (unpublished results). Two independent TGF-β type I recep-
tor kinase inhibitors appeared as hits at several concentrations (Fig. S2C); GW6004 showed effective concen-
trations between 1.1 and 30 μ M, whereas LY-364947 showed effective concentrations between 123 nM and 10 μ 
M. Analysis of the dose-response curves of several measurement parameters showed nice IC50 curves for both 
fibronectin texture and nuclear scattering/colony morphology (Fig. 2A). IC50 values of GW6604 (1.9 μ M) were 
one order of magnitude higher than the IC50 values of LY-364947 (0.2 μ M). Two more kinase inhibitors were 
identified as EMT blockers, oxindole I and glycogen synthase kinase 3β (GSK3β ) inhibitor I (Fig. S2C); whereas 
the GSK3β inhibitor I (CAS 667463-62-9) appeared as a hit, two independent GSK3β inhibitors included in the 
library failed to block EMT, waiving a reliable assignment of GSK3β activity in the EMT assay. In summary, a 
high-content assay was developed and validated to be applicable for medium- to high-throughput screening by 
using robotic liquid handling, automated imaging and image analysis.
High-throughput imaging screen for compounds that inhibit terminal EMT stages. A large 
screening campaign was performed in the 384-well format using the HCS platform ‘ArrayScan’. In total, 177 
plates covering several compound collections with 38,302 unique compounds were screened. TGF-β type I recep-
tor kinase inhibitors (GW6604 and LY-364947) were added as positive controls at five concentrations to gen-
erate standards of strong to very weak inhibition (Fig. S2D). In addition, staurosporine at high concentration 
was added to monitor toxicity. These control conditions helped data analysis, i.e. optimisation of clustering and 
threshold setting for hit definition. A brief flow-chart in Fig. 1D shows the data analysis process from raw data 
acquisition to final hit list generation. Overall, 63,897 data points were obtained from the entire screen, including 
control measurements and repeats of some small “focused” libraries (2–3 times) to verify repeatability of the 
assay. From two independent image analysis routines, 18 parameters were selected to create a multi-parametric 
profile for each well (Fig. S3) that described the phenotype induced by the compound. The parameters chosen 
were the most robust among several experiments, to a limited extent redundant and could be separated into 
groups of parameters describing fibronectin expression, size and morphology of colonies, distribution of nuclei, 
intensity and shape of nuclei and performance of the assay. Using multi-parametric profiles, toxic and EMT 
phenotypes were easily discriminated and the phenotypic strength of positive controls at different compound 
concentrations was very well represented (Fig. S3).
Since most of the compounds were screened as a single data point, the reproducibility of the assay was ana-
lysed using repeats of a small “focused” library of 2,000 compounds. The Pearson correlation coefficient for a 
single measurement parameter was 0.927 (Fig. 2B), indicating a very high reproducibility. The overall correla-
tion for all 18 parameters between three independent repeats was around 0.8 (Fig. S4A) showing that all cho-
sen parameters were very reproducible. Next, the quality of the assay was measured by calculation of the Z′ 
-factor17, a statistical parameter often used in the field of high-throughput screening. For the TGF-β receptor 
controls and the toxicity controls, the median Z′ -factors calculated from the Euclidian distance of the normalised 
multi-parametric profiles indicated that the assay was excellent for screening (GW6604 10 μ M, Z′ = 0.69; stauro-
sporine 0.1 μ M, Z′ = 0.66) (Fig. S4B). After normalisation of the data20, clustering and threshold-based filtering, 
93 unique compounds were identified as hits (Fig. 1D). The data analysis was done using the open-source data 
mining software KNIME21, and all statistical methods including normalisation, clustering, and threshold-based 
filtering were carefully optimised using the positive and negative controls. Finally, based on the analysis of the 
entire screen, the true positive rate (TPR) was 98.3% for the EMT inhibitor controls (GW6604, 10 and 3 μ M) and 
the false positive rate (FPR) was 0.21% for the dimethyl-sulfoxide (DMSO)-treated control cells. There were two 
minor technical issues in the vehicle controls which increased the FPR; after excluding affected wells the FPR was 
0.02%. The FPR of the toxicity control was 0%, and the hit rate of the library samples varied depending on the 
compound collection between 1.88% for a small focused library of kinase inhibitors to ~0.12% for compound 
collections with unknown biological activity. The overall hit rate for the library was 0.28%; without taking two 
focused libraries into account the hit rate was 0.17% (Fig. 2C). This demonstrates that the primary screen was 
highly specific and reproducible.
The hits were then verified and validated using a secondary assay measuring the effect on the direct down-
stream substrate of the TGF-β type I receptor, Smad2, which is phosphorylated at its C-terminus (p-Smad2) 
upon TGF-β signalling and translocates into the nucleus. p-Smad2 is a good marker for early TGF-β signalling 
selected (Fig. S3) from two individual image analysis algorithms (segmentation of nuclei as single cells and 
segmentation of grouped nuclei as colonies) were normalised plate-by-plate using the robust percentage-
of-control (.poc) method and then normalised per parameter using the Z score (.zscore) method within the 
open-source software KNIME (HCS-Tools extensions). Clustering was performed with the k-means algorithm 
using k = 5 after normalisation of parameters using the Euclidian distance (phenotypic strength). The cluster 
containing EMT inhibitors was filtered for phenotypic strength greater than 15 and finally the hit list was 
condensed to 93 unique compounds that were hits in the primary screen. To remove compounds interfering 
with TGF-β signalling, a counter screen was performed using the p-Smad2 assay (see Fig. S4C,D) and 16 
candidate EMT inhibitors were taken into further validation.
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Figure 2. Optimisation of HCS assay using GW6604 and compound hits. (A) Dose-response curves of 
TGF-β type I receptor kinase inhibitors LY-364947 (blue curves) and GW6604 (red curves) for four different 
parameters. The median IC50 value of GW6604 was 1.9 μ M and of LY-364947 was 0.2 μ M. The parameters 
describe the texture of fibronectin signal within a colony (group of cells) (EntropyInten), the minimum distance 
to a neighboring nucleus (NeighborMinDist), the percentage of colonies with lower texture measurement 
of fibronectin signal within a colony than the threshold derived from a control population of colonies 
(ContrastCoocInten), and the ratio of convex hull to perimeter of a colony (ObjectConvexHullPerimeterRatio). 
(B) The scatter plot of two repeated runs of 7 plates (n = 2576) shows very good linear correlation with a 
Pearson coefficient of 0.927 for a single texture parameter (fibronectin signal). Negative control wells and 
inactive compounds scatter around the zero coordinate, whereas controls show phenotype strength-dependent 
scattering along the diagonal. (C) Table of false positive rate (FPR) and true positive rate (TPR) for the entire 
screen. Using the strict threshold of Euclidian distance >15 for the EMT cluster, the strong EMT inhibitor 
controls (GW6604: 3 and 10 μ M) were identified as hits with a TPR of 98.3% and the negative control wells 
(DMSO) appeared as hits with a FPR of 0.21%. From the library 0.17% of wells were identified as hits.  
(D) Chemical structures of 16 compound hits. Simple heterocyclic and carboxylic acid analogs, steroidal and 
alkyl analogs, and extended multi-ring structures. Numbers correspond to the EPM IDs of each compound.
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and could be used to discriminate between general TGF-β inhibitors and selective late-stage EMT inhibitors 
(Fig. S4C). Translocation of p-Smad2 occurred within tens of minutes and the optimal time point of the assay 
determined via time course experiments was 1 hour after stimulation (Fig. S4D), which is in line with kinetic 
models obtained from experimental data in HaCaT cells22. Hits having no or little effect on translocation of 
p-Smad2 were selected as the most interesting compounds (Fig. S5). In addition, compounds that could not be 
verified and failed to generate reproducible phenotypes were also excluded. In summary, 35 compounds (38% 
of all hits) gave once or twice a reproducible EMT phenotype in two experimental repeats (Figs S5 and S6A). 
Scatter plot analysis of p-Smad2 nuclear translocation versus strength of phenotype allowed us divide the 35 
verified compounds into groups of compounds that behaved like TGF-β receptor inhibitors and compounds that 
had no or little effect on p-Smad2 nuclear translocation (Fig. S6B). We found three compounds (CBN::49::1::14, 
CBN::42::7::9 and KBI::2::5::6) that inhibited p-Smad2 nuclear translocation and which had similarities in their 
molecular structure with known TGF-β receptor inhibitors (Fig. S6C). In fact, KBI::2::5::6 is an established TGF-β 
type I receptor inhibitor and is widely known as SB-431542. This is in agreement with independent high content 
screens for EMT inhibitors, where the majority of chemical compounds identified are proven to act as TGF-β 
receptor inhibitors18. Considering all experimental data points, the molecular structure of the hits and certain 
proprietary reasons, 19 compounds were finally excluded from the hit list (Figs S5 and S6A,B). However, deeper 
analysis of the excluded compounds may be interesting in terms of uncovering novel modulators of TGF-β /Smad 
signaling.
After analysis of the verification and the counter-screen, 16 compounds were identified as candidates for inhi-
bition of EMT without affecting TGF-β -induced p-Smad2 nuclear accumulation (Fig. 1D). The hits could be clas-
sified into three chemical classes: simple heterocyclic and carboxylic acid analogs (5 compounds), steroidal-alkyl 
analogs (5 compounds) and extended multi-ring analogs (6 compounds) (Fig. 2D). We conclude that the 
high-content screen identified specific chemical compounds that block terminal EMT and mesenchymal-specific 
fibronectin accumulation without affecting basal TGF-β signalling. None of the identified compounds resembled 
chemicals with previously described functional roles in modulating epithelial plasticity.
A selective sub-group of compounds points to the action of hydroxycholesterol. Based on their 
commercial availability, we focused on 13 of the 16 confirmed hits from the screen (Fig. 2D). We refer to these 
compounds as epithelial plasticity modulators (EPMs) and in the case where the compounds have known biolog-
ical effects, their common names are also listed. We verified the activities of these hits in HaCaT cells by analysing 
their effects (from low nM to a maximum of 10 μ M) on epithelial-mesenchymal protein markers, but for simplicity 
we present selected sets of expression data i.e. on the mesenchymal fibronectin, the epithelial claudin-3 and Smad3 
C-terminal phosphorylation (p-Smad3) as a direct readout of TGF-β signalling (Fig. 3A). Inhibitor GW6604 
served as a positive control; it inhibited phosphorylation of Smad3, blocked fibronectin and restored claudin-3 
expression. The 13 hits demonstrated distinct phenotypic profiles with respect to these three markers (see also 
summary in Table S1). For example, EPM-6 (acivicin) partially blocked TGF-β -induced fibronectin expression 
without reverting the claudin-3 levels, and left p-Smad3 intact (Fig. 3A). EPM-12 showed a partial reversion of 
claudin-3 without affecting strongly fibronectin, however, this compound weakly decreased p-Smad3 (Fig. 3A). 
EPM-1 (24(S)-hydroxycholesterol), EPM-2 (estradiol valerate), EPM-4 (lanosterol), and EPM-5 (4-nonylphenol), 
all had inhibitory effects on fibronectin without perturbing claudin-3 or p-Smad3 (Fig. 3A). Among the extended 
multi-ring compounds, EPM-11, 13 and 15 had the strongest effects, and inhibited not only fibronectin but 
also reverted the epithelial claudin-3, again without showing significant interference with p-Smad3 activation 
(Fig. 3A). Based on their potency and effects, a few compounds were selected for further studies.
EPM-1 dose-dependently blocked fibronectin expression without affecting epithelial claudin-3 (Fig. 3B). 
EPM-1 was a more potent inhibitor when added simultaneously with TGF-β 1, but its inhibitory activity per-
sisted even when added 72 h after TGF-β 1 stimulation (Fig. 3C). EPM-13 exhibited a similar potency to EPM-1 
in blocking fibronectin, but also partially reverted epithelial claudin-3 levels (Fig. 3B) and seemed to have the 
strongest effect when added simultaneously with TGF-β (Fig. 3C). The action of EPM-13 as an anti-EMT blocker 
was verified by immunofluorescence experiments; in the presence of EPM-13, TGF-β -induced mesenchymal 
cells regained their plasma membrane E-cadherin and downregulated their intense stress fibers, exhibiting a 
morphological reversion comparable to the reversion caused by GW6604 (Fig. 3D,E). A similar result was found 
for EPM-10, a second extended multi-ring inhibitor; although EPM-10 did not score well for reversion of the 
epithelial claudin-3 or CAR upon immunoblot analysis (Fig. S7A,B); immunofluorescence microscopy clearly 
verified that EPM-10 blocked the pro-EMT effect of TGF-β and generated tightly assembled cell islets with well 
formed adherens junctions and cortical actin (Fig. S7C–E). Using the HaCaT islet density assay described for the 
high-content screen, we also verified that both EPM-10 and EPM-13 induced reappearance of dense islets, similar 
to the effect of GW6604, when compared to the intense cell scattering induced by TGF-β (Figs S7E and S8A,B).
Since EMT is mediated by a specific group of transcription factors and chromatin regulators15,16, we assayed the 
expression of several members of this functional group that are potently induced by TGF-β in HaCaT cells, includ-
ing Snail1, Snail2, ZEB1, Twist1 and high mobility group A2 (HMGA2) (Fig. 4A,B). As expected, EPM-10 and 
EPM-13 blocked the induction of Snail1 and Snail2 by TGF-β in HaCaT cells, but even EPM-1 potently suppressed 
Snail1 and Snail2 induction by TGF-β (Fig. 4A,B). Unexpectedly though, EPM-1 seemed to reproducibly induce 
Snail1 and Snail2 expression in the absence of TGF-β stimulation, an observation that could not be correlated with 
the basal effects of EPM-1 on epithelial and mesenchymal markers in the same cells (Fig. 3). In contrast EPM-10 
and EPM-13 had no effect on basal Snail1 or Snail2 expression (Fig. 4A,B). On the other hand, ZEB1, Twist1 and 
HMGA2 expression did not significantly change in the presence of these compounds in HaCaT cells (unpublished 
results). In a two-dimensional migration assay of human prostatic carcinoma PC3U cells, after a linear wound, 
EPM-13 failed to block cell migration, whereas EPM-10 was as potent as GW6604 (Fig. S8C). Collectively, the 
various cell-based assays confirmed that individual EPMs exhibited distinct profiles of biological activities.
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Figure 3. Analysis of 13 selected compounds in keratinocytes. (A–C) Protein expression analysis in HaCaT 
total cell lysates stimulated (+ ) or not (− ) with 5 ng/ml TGF-β for 96 h. In (A) cells were co-treated with 
DMSO or specific EPMs (10 μ M). In (B) cells were co-treated with DMSO (0 μ M) or EPM-1 and EPM-13 at the 
indicated concentrations. In (C) cells were co-treated with DMSO (0 μ M) or EPM-1 and EPM-13 (10 μ M) at 
the indicated time points following TGF-β stimulation. Immunoblots for the indicated proteins and Gapdh, the 
protein loading control, are shown. (D) E-cadherin immunofluorescence microscopy of HaCaT cells stimulated 
with vehicle or 5 ng/ml TGF-β for 96 h in the presence of DMSO or 10 μ M of EPM-13 or 3.3 μ M GW6604 
(GW). (E) Actin microfilament direct fluorescence microscopy of HaCaT cells treated as in panel D. White bars 
indicate 10 μ m.
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Figure 4. Compounds that could suppress EMT transcription factor expression in HaCaT cells. (A,B) mRNA 
expression analysis of Snail1 (A) and Snail2 (B) in HaCaT cells in the absence or presence of 5 ng/ml TGF-β for 
72 h, and in the presence of DMSO or specific compound (EPM-1, EPM-10 and EPM-13), analysed by real-time 
RT-PCR and normalised against the housekeeping Gapdh mRNA. The data are expressed as bar graphs of average 
determinations with corresponding standard errors from triplicate determinations. Stars indicate significant 
difference at p < 0.05. (C,D) Number (C) and size (D) of hepatospheres grown in hanging drops using Insphero 
assays in the presence of control, DMSO or 10 μ M EPM-1. The data are expressed as bar graphs of average 
determinations with corresponding standard errors from triplicate determinations. Stars indicate significant 
difference at p < 0.05. (E) Representative phase contrast images of hepatospheres grown in hanging drops using 
Insphero assays in the presence of control, DMSO or 10 μ M EPM-1. (F) Protein expression analysis in the 
hepatospheres treated with DMSO or 10 μ M EPM-1 under the same conditions as in panels C-E. Immunoblots for 
the indicated proteins and Gapdh, the protein loading control, are shown.
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We confirmed compound bioactivity in human cancer cells by testing all 13 compounds in lung adenocarci-
noma A549 (not shown), breast cancer MCF10A-MII (Fig. S9) and hepatocellular carcinoma (HCC) Hep3B cells 
(Fig. S10); the results were comparable to HaCaT cells. In the MCF10A-MII cell model, the impact of many com-
pounds was evident by microscopic analysis of general cell morphology (Fig. S9A), downregulation of fibronectin 
expression without corresponding effects on E-cadherin or plasminogen activator inhibitor 1 (PAI-1), the latter 
serving as a marker of TGF-β responsiveness that is independent of cell type (Fig. S9B). In HCCs, EPM-5, -6, 
-11 and -12 reproducibly blocked the expression of fibronectin, without strong effects on E-cadherin expression 
(Fig. S10A–C).
We also tested whether specific compounds could affect cancer stem cell features known to be functionally 
linked to the process of EMT1, or whether the compounds could alter the mesenchymal phenotype of tumor 
cells outside the context of TGF-β signaling. Experiments were performed in the mesenchymal HCC cell model 
SNU423, for which 3-dimensional hepatospheres can be generated by culturing the cells using the hanging drop 
method (Figs 4C–F and S11). In these assays, mainly EPM-1, EPM-10 and EPM-13 were analysed. Whereas 
EPM-1 had a significant effect on increasing the number and size of spheres (Fig. 4C–E), EPM-10 and EPM-13 
did not significantly alter the hepatosphere phenotype, although a trend towards increased sphere size could be 
recorded (Fig. S11). As these results were not encouraging, we did not perform a deeper analysis of the effects 
of these compounds on the expression of marker genes for cancer stem cells. However, analysis of mesenchymal 
proteins such as fibronectin and N-cadherin that are constitutively expressed by SNU423 cells were found to be 
significantly downregulated by EPM-1 and EPM-10 in the hepatospheres (Figs 4F and S11D), whereas EPM-13 
had no clear effect on these two mesenchymal proteins (Fig. S11H). It is therefore possible that some of these 
compounds could suppress mesenchymal cell features of tumor cells but further analysis will be required.
Based on the various cell models employed thus far in the study, we conclude that select compounds identi-
fied using our screening approach reverted mesenchymal cells back to the epithelial phenotype (EPM-10/-13), 
whereas the majority of compounds, including EPM-1, showed good inhibition of mesenchymal features without 
fully reverting cells to an epithelial phenotype. A summary of the activity of the tested compounds appears in 
Table S1.
Inhibition of myofibroblast differentiation. EMT generates transitory mesenchymal cells, and resem-
bles the TGF-β -induced conversion of fibroblasts to terminally differentiated myofibroblasts8. Myofibroblasts 
specialise in matrix production, and our lead compounds inhibited expression of the matrix component fibronec-
tin in response to TGF-β . We therefore hypothesised that these compounds might block the matrix-producing 
myofibroblast phenotype. We tested all 13 compounds for their effects in a model of myofibroblast differentiation 
using human immortalised fibroblasts HTERT (Fig. 5). α SMA was monitored as a specific marker of myofibro-
blast differentiation, and PAI-1 as a marker of TGF-β responsiveness (Fig. 5A). The compounds blocked fibronec-
tin expression without affecting TGF-β -induced PAI-1 expression; however, EPM-1, -2, -4, -6, -11, -12, -13 and 
-15, strongly blocked α SMA expression and did so more potently than inhibiting fibronectin (Fig. 5A). The effects 
were confirmed in dose-dependent experiments (Fig. 5B showing EPM-6 and -1). The quantitative effect on pro-
tein expression was also evident at the level of total actin microfilaments stained with phalloidin (Fig. 5C). TGF-β 
induced a strong F-actin network that was blocked by EPM-6 and EPM-1.
Based on their reported biological mechanisms, we expanded our characterisation of EPM-1, -2, -5 and -6 by 
testing analogs of these compounds that have known cellular targets. EPM-6 (acivicin) is an irreversible inhibitor 
of glutamine-dependent amidotransferases including glutamate synthase and GMP synthase (as well as enzymes 
such as γ -glutamyl transpeptidase), and has been tested as a chemotherapeutic against various human cancers23,24. 
In order to evaluate the impact of broadly inhibiting glutamine-based metabolism and specific enzymes targeted 
by acivicin25, we tested the glutamine analogs azaserine and DON23, and the GMP synthase inhibitor decoyinine. 
None of these compounds had any impact on α SMA, but the two glutamine analogs, azaserine and DON, sig-
nificantly decreased fibronectin expression (Fig. 5D). Hence, it is likely that acivicin affects cell plasticity not via 
effects on glutamine metabolism per se but via as yet unknown bioactivities.
Intriguingly, EPM-1 (24(S)-hydroxycholesterol), EPM-2 (estradiol valerate) and EPM-5 (4-nonylphenol) 
are known agonists of the liver X receptors, the estrogen receptors (ERs), and the pregnane X receptor (PXR), 
respectively. Given that our screening strategy identified multiple nuclear receptor ligands, we tested an expanded 
set of nuclear receptor agonists and antagonists to identify potential targets with the greatest impact on myofi-
broblast differentiation. This list of compounds included agonists and antagonists of the LXRs, ERs, proges-
terone receptor (PR), PXR and constitutive androstane receptor (CAnR) (Fig. S12A). Like EPM-1, a natural 
(24(S), 25-epoxycholesterol) and two synthetic (T0901317, GW3965) LXR agonists potently blocked α SMA and 
fibronectin induction by TGF-β in HTERT fibroblasts, whereas two LXR antagonists (Tularik Compound 54, 
GSK 2033) had no effect (Fig. 5D). No obvious effect on general TGF-β signalling was observed as assessed by 
monitoring PAI-1 expression (Fig. 5D). The PXR agonist SR12813 blocked α SMA levels but also affected PAI-1, 
whereas another, pregnenolone-16α -carbonitrile (PCN), had no effects. The two CAnR agonists, TCPOBOP and 
CITCO, had weak effects. Finally, the ER and PR ligands showed equally potent inhibitory effects against α SMA, 
with tamoxifen exhibiting most potent inhibition against α SMA expression but variable effects on fibronectin 
levels (Fig. 5D).
All these compounds were also tested in the HCC Hep3B model in addition to a few more compounds, includ-
ing two synthetic LXR agonists (GSK3987, WYE672), which downregulated TGF-β -induced fibronectin (Fig. S10 
and unpublished results). Further, consistent with their lack of activity on the LXRs, 24(R)-27-hydroxycholesterol 
and 22(R)-hydroxycholesterol had no impact on fibronectin in Hep3B cells (Fig. S10A). Overall, similar to fibro-
blasts or other epithelial cells, all LXR agonists reduced HCC fibronectin expression in a dose-dependent manner 
(Fig. S10D,E).
www.nature.com/scientificreports/
1 0Scientific RepoRts | 6:29868 | DOI: 10.1038/srep29868
Figure 5. Analysis of 13 selected compounds in HTERT fibroblasts. (A,B) Protein expression analysis 
in HTERT total cell lysates stimulated (+ ) or not (− ) with 5 ng/ml TGF-β for 72 h and co-treated with (A) 
DMSO or specific EPMs (10 μ M); (B) DMSO (0 μ M) or EPM-6 and EPM-1 at the indicated concentrations. 
Immunoblots for the indicated proteins and for Gapdh, the protein loading control, are shown. (C) Actin 
microfilament direct fluorescence microscopy of HTERT cells stimulated with vehicle or 5 ng/ml TGF-β for 72 h 
in the presence of DMSO or 10 μ M of EPM-6 and EPM-1. White bar indicates 10 μ m. (D) Protein expression 
analysis in HTERT total cell lysates stimulated (+ ) or not (− ) with 5 ng/ml TGF-β for 72 h and co-treated with 
DMSO or specific compounds (10 μ M). Immunoblot for the indicated proteins and for Gapdh, the protein 
loading control, are shown.
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Based on the robust pharmacology of LXR ligands observed in our screening, we focused on understand-
ing their impact on myofibroblast differentiation. In two different human fibroblast models that differentiate to 
myofibroblasts in response to TGF-β (HTERT and primary AG1523), all LXR agonists tested dose-dependently 
Figure 6. LXR agonists block myofibroblast differentiation. (A) Protein expression analysis in HTERT and 
AG1523 total cell lysates stimulated (+ ) or not (− ) with 5 ng/ml TGF-β for 72 h and co-treated with DMSO 
(0 μ M) or specific T0901317 (T0) compound at the indicated concentrations. Immunoblots for the indicated 
proteins and for Gapdh, the protein loading control, are shown. (B) α SMA microfilament immunofluorescence 
microscopy in AG1523 cells stimulated with vehicle or 5 ng/ml TGF-β for 72 h in the presence of DMSO or 
10 μ M of T0901317 and 3.3 μ M GW6604 (GW). Images stained blue for DAPI-positive nuclei, red for F-actin 
microfilaments and green for α SMA microfilaments. White bar indicates 10 μ m. (C) Protein expression analysis 
in AG1523 total cell lysates stimulated (+ ) or not (− ) with 5 ng/ml TGF-β for 72 h in the presence of DMSO 
(control) or the indicated LXR agonists. β -Actin serves as a loading control. (D) Collagen gel contraction assay 
performed on AG1523 cells stimulated (+ ) or not (− ) with 5 ng/ml TGF-β for 72 h in the presence of LXR 
agonist T0901317 or DMSO (control). A representative image and corresponding quantification of contracted 
gels graphed as average of 5 repeats with associated standard deviation. A star indicates statistically significant 
difference at p < 0.05. (E) Protein expression analysis in AG1523 total cell lysates stimulated (+ ) or not (− ) with 
5 ng/ml TGF-β for 24 h and co-treated with DMSO (0 μ M) or specific T0901317 (T0) compound at the indicated 
concentrations. Immunoblots for the indicated proteins and for Gapdh, the protein loading control, are shown.
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blocked TGF-β -inducible fibronectin and α SMA (Fig. 6A,B showing data for T0901317; Fig. S12C–E showing 
data for 24, 25-EC and GW3965). Microscopic analysis also demonstrated a block of actin microfilament assem-
blies by all three LXR agonists and most potently by GW3965 (Fig. S12E). Side-by-side comparison of each of 
these agonists showed a strong reduction in the TGF-β -induced expression of additional myofibroblast mark-
ers (calponin, SM22-α ) without affecting basal levels of the proteins (Fig. 6C). Functionally, T0901317 inhib-
ited TGF-β -mediated contraction of collagen gels by differentiated myofibroblasts (Fig. 6D, 19.5 ± 0.3% versus 
34.8 ± 2.8% of initial gel area, p < 0.05). Results were confirmed using additional LXR agonists (24, 25-EC and 
GW3965) or the LXR antagonist GSK2033 (Fig. S13). The LXR agonist, 24, 25-EC, which is known to be less 
potent, blocked TGF-β -induced collagen contraction but not as efficiently as the other two agonists (Fig. S13A). 
The GW3965 agonist also blocked TGF-β -induced collagen gel contraction (Fig. S13B, reproducing the effect of 
T0901317 (Fig. 6D and Fig. S13C showing data at 48 h). Finally, the LXR antagonist, GSK2033, had no impact 
on TGF-β -induced collagen gel contraction (Fig. S13D). As previously stated, T0901317 did not reduce central 
TGF-β signalling (monitored as p-Smad3 and PAI-1, Fig. 6E). We conclude that agonistic activation of LXR func-
tion blocks myofibroblast differentiation induced by TGF-β .
LXRα protects fibroblasts from myofibroblast differentiation. As the previous experiments ana-
lysed physiological effects of the LXR agonists on fibroblasts (Fig. 6), we next assayed for LXR expression in these 
cells (Figs 7A and S14A,B). Detectable mRNA levels of both LXRα and LXRβ were measured in AG1523 fibro-
blasts (Fig. S14A). Interestingly, TGF-β stimulation suppressed LXRα expression (>50%), whereas LXRβ was 
induced up to 1.5-fold (Fig. S14A). The expression and regulation of LXR isoforms by TGF-β was confirmed at 
the protein level (Figs 7A and S14B). Since the LXR proteins are expressed at rather low levels in the cells that we 
analysed, and available antibodies are not so reliable, we confirmed the identity of each LXR isoform after trans-
fection of the fibroblasts with short hairpin RNAs that target each specific isoform (Fig. 7A,B). Whereas T0901317 
reproducibly stabilised the protein levels of LXRα and LXRβ , TGF-β downregulated LXRα and upregulated LXRβ 
to a low but significant degree (Figs 7A,B, S14B). In order to explore the roles of LXRα and LXRβ in myofibroblast 
differentiation, transient knockdown of LXRα or LXRβ was effective at both mRNA and protein levels (Figs 7C 
and S14C). TGF-β -induced α SMA expression was further enhanced after silencing LXRα , whereas LXRβ silenc-
ing had no effect (Figs 7C and S14C). The LXRα knockdown was not sufficient to increase α SMA in the absence 
of TGF-β and this is most likely because in this cell system, myofibroblast differentiation is TGF-β -dependent. 
Since LXRα knockdown does not activate autocrine TGF-β signaling, the differentiation process remains depend-
ent on exposure to exogenous TGF-β . Conversely, transient expression of exogenous LXRα in mouse embryonic 
fibroblasts (MEFs) caused reproducible repression of TGF-β -induced α SMA (Fig. 7D). Fluorescence microscopy 
for endogenous F-actin and α SMA demonstrated that LXRα downregulated completely α SMA and to a lower 
extent F-actin microfilaments (Fig. 7E). Silencing or overexpression of LXRα had no effect on p-Smad3 or PAI-1 
activation by TGF-β (Fig. 7C,D), neither did we observe effects of the LXR agonist (T0191317) on the activity of 
a Smad-specific promoter-luciferase reporter (CAGA12-luc) (Fig. S14D), nor did silencing of endogenous LXRα 
affect the activity of the CAGA12-luc reporter (unpublished results). Functionally, LXRα overexpression inhibited 
TGF-β -mediated contraction of collagen gels by myofibroblasts (Fig. 7F, 11.7± 0.9% versus 43.6± 3.4% of initial 
gel area, p < 0.05). Collectively, these data suggest that TGF-β negatively regulates LXRα in fibroblasts, which is 
physiologically important as LXRα counteracts the pro-fibrotic effect of TGF-β .
Discussion
Our screen for chemical modulators of EMT identified compounds with diverse biological activities and included 
new compounds that affect myofibroblast differentiation, a process relevant to fibrosis and cancer7,8,11. The rela-
tively small number (16) of final hits identified show structural diversity, providing a diverse group of compounds 
that affect epithelial plasticity and myofibroblast differentiation in distinct ways (Table S1). These compounds 
may find use in further studies of the intermediate stages of EMT, the deeper understanding of myofibroblast dif-
ferentiation and, as we discuss later for LXR agonists, they may also suggest new ways of combinatorial treatment 
for fibrotic and cancer pathologies.
Because the analysis of epithelial plasticity largely depends on cell biological parameters3,4,26, cell-based 
screens using high-content imaging systems are important27,28. This technology has advanced dramatically, and 
has been applied to cell biological processes as complex as vesicular trafficking29,30.
The HaCaT keratinocytes employed are well studied in the TGF-β field as they faithfully undergo EMT14,15,16. 
Due to the discriminative power of the high-content robotic microscope, we used a single marker of mesenchy-
mal/fibroblast differentiation, i.e. fibronectin, which was sufficient to generate successful chemical hits from the 
screen. Although our initial plan was to use multiple markers in order to more accurately monitor the reversion of 
EMT, analysis of the expression and localisation of markers such as E-cadherin, vimentin and the actin cytoskel-
eton (unpublished results and Fig. S2B), did not generate reliable discriminatory power or reproducible imaging 
profiles that were sufficient for quantitative analysis in a high-throughput setting. This experience coincides with 
findings from the recently published imaging screen that also scored fibronectin as a reliable marker of “terminal” 
stages of EMT, which could then be reverted back to its basal epithelial levels18. Despite the current limitations, we 
anticipate that future screens based on multiple protein markers may allow for a more complex analysis of inter-
mediate stages and sub-programs of the EMT process. Although the cell model employed was absolutely depend-
ent on stimulations with exogenous TGF-β , the counter-screen against direct regulators of Smad phosphorylation 
coupled with the late time point of compound addition allowed us to study the late stages of plasticity progression; 
we propose that late stages depend on initial TGF-β stimulation but are eventually sustained by other factors.
The detailed evaluation of the 13 compounds provided some general points. Certain extended multi-ring 
scaffolds can potently revert a mesenchymal phenotype towards an epithelial (EPM-10 and -13, Figs 3 and 4 
and S7–9). EPM-10 and -13 promote the rebuilding of adherens junctions without blocking TGF-β signalling or 
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Figure 7. LXRα inhibits TGF-β-induced myofibroblast differentiation. (A–D) Protein expression analysis 
in AG1523 (A–C) and MEF (D) total cell lysates stimulated (+ ) or not (− ) with 5 ng/ml TGF-β for 72 h 
(A–D) or 24 h (C). In (A,B) AG1523 cells were stimulated with the LXR agonist T0901317 for 24 h in order to 
stabilise LXRα and LXRβ , thus providing evidence for the specificity of the detected protein band. In (A, B) 
AG1523 cells were also transfected with shRNA vectors targeting LXRα (A) and LXRβ (B) in order to show 
specificity of the detected protein band. In (C) AG1523 were transfected with the indicated siRNAs. In (D) 
MEFs were transiently transfected with LXRα cDNA vector. Immunoblots for the indicated proteins and 
for Gapdh, the protein loading control, are shown. Arrows mark the specific protein bands. (E) Direct and 
immunofluorescence microscopy of MEFs transfected and stimulated as in panel C and analysed for total 
F-actin and α SMA microfilaments. White bar indicates 10 μ m. (F) Collagen gel contraction assay of MEFs 
transfected with LXRα cDNA vector (or control vector) and stimulated (+ ) or not (− ) with 5 ng/ml TGF-β for 
72 h. Quantification of the surface area of contracted gels is presented as in Fig. 6D (star: statistically significant 
difference at p < 0.05).
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rescuing the temporal degradation of tight junction components (Figs 3 and S7). Searches based on the molecular 
structure of these compounds have not yet allowed us to identify specific cellular targets of their activity. An unbi-
ased approach of molecularly “fishing” for biomolecules that associate with EPM-10/-13 may provide interesting 
clues for their targets. In addition to these compounds, acivicin, an inhibitor of glutamate, nucleoside and glu-
tathione biosynthesis, clearly regulates epithelial plasticity (Figs 3 and 4). However, the lack of similar effects by 
azaserine and DON raises doubts about the general importance of glutamine metabolism on plasticity and point 
to other, unknown targets of acivicin. Acivicin has been extensively studied in the context of cancer, but failed in 
several clinical trials due to toxicity issues23,24.
Several groups of nuclear receptor agonists scored prominently in our screens, such as the LXR and ER/PR 
ligands (Figs 5D, 6 and S10). While the findings with ER/PR ligands are interesting, we focused on LXR because 
of the robust and consistent results seen with all compounds tested from this family (Fig. 5). Clearly, LXR ago-
nism inhibits progression of fibroblasts to the myofibroblast phenotype or epithelial HCC to the mesenchymal 
phenotype (Figs 6 and S12 and S13). A good area for deeper elucidation of the crosstalk between LXR and TGF-β 
signalling is the αSMA gene and its regulatory sequences. Our mechanistic evidence shows a negative role of 
LXRα on TGF-β -mediated myofibroblast differentiation and αSMA gene regulation (Figs 7 and S14). In addition, 
TGF-β signalling negatively regulates the abundance of LXRα in fibroblasts (Figs 7A and S14A,B), suggesting 
that the fibrotic program of TGF-β may depend on removal of the protective role of LXRα . Since the biological 
functions of LXRs are well understood in the liver, the role of LXR in modulating liver fibrosis and cancer pro-
gression is worth examining in detail. Observations in mouse models provide further support for this notion. 
LXRα (but not LXRβ ) knockout mice exhibited stromal overgrowth around the prostatic epithelium, with high 
levels of α SMA and high TGF-β signalling activity in the stroma31. Furthermore, the LXR agonist T0901317 was 
shown to protect against bleomycin-induced mouse skin fibrosis; however, LXR function in this model was found 
to be directed towards resident macrophages that secreted interleukin-6, which then suppressed myofibroblast 
differentiation32. Recently, in a model of cardiac fibrosis after aortic constriction, the LXR agonist AZ876 success-
fully blocked fibrosis by inhibiting the effects of TGF-β on vascular smooth muscle differentiation and α SMA 
induction33. Although some of these in vivo studies favor the action of macrophages or other unidentified stromal 
cells as those that respond to LXR agonists31,33, our evidence using three established fibroblast models (HTERT, 
AG1523 and MEFs) suggests that fibroblasts can respond to LXR agonists and even more importantly, LXR levels 
can be modulated by TGF-β signalling (Figs 7 and S14). Overall, the potential clinical utility of LXR agonists for 
lipid disorders12,13, and our evidence from in vitro cell models, suggest that LXR agonists may be useful for future 
combinatorial treatments of tissue fibrosis and advanced stages of cancer.
Functions of different members of the nuclear receptor superfamily have been previously linked to the regula-
tion of the EMT in a diverse set of cancer and fibrotic conditions34–36. The estrogen receptor α (ERα ) protects epi-
thelial differentiation and acts as an anti-EMT factor especially in the mammary gland, as it directly represses the 
expression of Snail2; conversely, Snail1 transcriptionally represses the ERα gene during EMT34. Similar functions 
have been etsbalished for ERβ in the prostate, where loss of ERβ promotes Snail1 function by releasing expression 
of the vascular endothelial growth factor α 37. The glucocorticoid and androgen receptors also block EMT pro-
gression, although the case of the androgen receptor in the prostate is complicated as both positive and negative 
effects of this protein on EMT have been reported36. The peroxisome proliferator-activated receptor γ (PPARγ 
) and its agonists block TGF-β -induced EMT in lung cancer cells and suppress metastasis in recipient mice38. 
PPARγ seems to act as a transcriptional repressor of nuclear Smad3 activity, thus limiting the potential of TGF-β 
to regulate the target genes that enforce the EMT. On the other hand, the retinoic acid receptor β contributes to 
the generation of a myofibroblast-rich stroma that promotes breast cancer progression39.
Nuclear receptor function, in particular PPARγ , has also been linked to tissue fibrosis by regulating both EMT 
and myofibroblast activation40,41. Many agonists of PPARγ have shown promising anti-fibrotic effects in the lung 
and other organs40,41, and the activity of PPARγ is important in epithelial cells but also in stromal fibroblasts, 
where their activation towards myofibroblasts is blocked by PPARγ agonists. However, the action of PPARγ ago-
nists may involve more complex mechanisms, even independent from this receptor40,41.
Systematic screens for agents that affect plastic changes in epithelial tissues have shown utility in cancer ther-
apy. In ovarian and colorectal cancer, pre-screening for a set of EMT marker genes provides useful diagnostic 
power for the prediction of chemotherapy response in patients26. Based on the classification of intermediate 
EMT states, a population of ovarian cancers that exhibits intermediate mesenchymal differentiation was most 
sensitive to the Src kinase inhibitor saracatinib, which induced epithelial features and decreased the stem-like 
properties of the tumour cells3. Src and its associated focal adhesion kinase provide resistance of mesenchymal 
variants in non-small cell lung cancer to chemotherapeutic drugs, and the Src inhibitor dasatinib renders these 
tumours susceptible to anti-cancer agents such as erlotinib42. Attempts to define novel compounds that could 
interfere with EMT have reconfirmed major established inducers of EMT, such as TGF-β receptors, the Src kinase 
and MAPKs27. A screen of natural products for their ability to re-epithelialise metastatic and highly mesenchy-
mal breast cancer cells identified the triterpenoid sarasinoside A, which induced intercellular tight junction and 
activation of the small GTPase Rap143. An independent imaging-based screen for lung adenocarcinoma EMT 
inhibitors identified methacycline, a compound that interfered with specific MAPK pathways acting downstream 
of TGF-β ; in vivo, methacycline blocked the lung fibrosis induced by bleomycin, without perturbing central 
responses to TGF-β signalling in various stromal cell types28.
In conclusion, our high-content imaging screen identified chemical agents that can be used for studies aimed 
at deciphering the cell biological parameters that specify intermediate, or rather, late stages in the plasticity pro-
gression. In addition, the new evidence that certain nuclear receptors protect epithelial cells from pro-fibrotic 
evolution and also prevent fibroblasts from differentiating towards myofibroblasts, provides an example of how 
crosstalk between TGF-β signalling and nuclear receptors can generate new avenues for basic and translationally 
applicable future investigations.
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Methods
Cell transfection. AG1523 fibroblasts were seeded at 50% confluence in 6-well culture dishes and trans-
fection was performed using Silentfect (Bio-Rad Laboratories AB, Solna, Sweden) as per the manufacturer’s 
instructions. Control siRNA, LXR-α or LXR-β siRNA were added to the cells at 50 nM for 24 h at which point 
the medium was changed to serum-free medium containing 5 ng/ml TGF-β or vehicle. Cells were maintained 
for an additional 24 h in TGF-β and then harvested for RT-PCR or immunoblotting. For luciferase and shRNA 
silencing assays, AG1523 fibroblasts were transfected as above except that Lipofectamine 3000 (Invitrogen/Life 
Technologies Corp., Foster City, CA, USA) replaced Silenfect.
MEFs were seeded at 70% confluence in 6-well dishes and transfection was performed using Fugene HD 
(Roche Diagnostics Scandinavia AB, Bromma, Sweden) according to the manufacturer’s protocol (6:1 (v/v) 
Fugene to DNA ratio). Twenty four hours after transfection, cells were stimulated with TGF-β for 72 h prior to 
harvesting lysates for immunoblot of fixing cells for immunofluorescence.
Immunoblotting. Following the indicated treatments, cells were washed once in ice-cold PBS and proteins 
were collected in lysis buffer (20 mM Tris-HCl pH 8.0, 1% NP-40, 150 mM NaCl, 2 mM EDTA) supplemented 
with protease inhibitor cocktail (Roche Diagnostics Scandinavia AB, Bromma, Sweden) and cleared by centrifu-
gation at 14,000x g at 4 °C for 10 min. Lysate protein concentration was measured by a Bradford assay. Equal pro-
tein amounts from each sample were separated with sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
and transferred to a nitrocellulose membrane. Membranes were blocked for 1 h in 5% milk/TBS-T and incubated 
overnight at 4 °C with primary antibody in TBS-T. Following 3 washes in TBS-T, corresponding HRP-conjugated 
secondary antibody (Invitrogen/Life Technologies Corp., Foster City, CA, USA) was added in TBS-T at a con-
centration of 1:20,000 (anti-mouse) or 1:40,000 (anti-rabbit) and incubation prolonged for 1 h at room tempera-
ture. Antibody binding was visualised with the enhanced chemiluminescence detection system (Thermo Fischer 
Scientific Inc., Waltham, MA, USA). Images were captured with a Fuji scanner using the AIDA software (Fuji 
Inc.) and band intensities were calculated using Photoshop CS3.
Immunofluorescence and direct fluorescence microscopy. Immunofluorescence experiments were 
performed on cells seeded onto sterile glass cover slips in 6-well culture dishes. Following the indicated treat-
ments, cells were fixed for 20 min in 3.7% v/v para-formaldehyde in PBS, permeabilised with 0.1% Triton X-100 
in PBS for 20 min, blocked for 30 min with 1% BSA in PBS and incubated overnight at 4 °C with the indicated 
primary antibody at a concentration of 1:500 in 1% w/v BSA. Following primary antibody binding, cells were 
incubated with anti-mouse Alexa-fluor488 conjugated secondary antibody (Invitrogen/Life Technologies Corp., 
Foster City, CA, USA) at a concentration of 1:1,000 in 1% w/v BSA for 1 h at room temperature in the dark. 
To visualise F-actin, permeabilised cells were stained for 20 min with phalloidin conjugated to Alexa-fluor594 
(Invitrogen/Life Technologies Corp., Foster City, CA, USA). A minimum of three washes was performed between 
each of the above mentioned steps. Following the last set of washes, cover slips were placed onto glass slides with 
VectaShield HardSet mounting medium containing DAPI (Vector Laboratories, Life Technologies Corp., Foster 
City, CA, USA) for visualisation.
Real Time RT-PCR. Total RNA was analysed by quantitative RT-PCR as described14, using specific PCR 
primers (see Extended view). A two-tailed paired Student’s t-test (significance at P value < 0.05) was used to com-
pare TGF-β -inducible levels after control or LXR-specific knockdown in triplicate determinations.
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